Monitor ESMO 2026 presentations (Oct 23-27) for actual efficacy and safety data from the pumitamig + docetaxel Phase 2 trial and the pumitamig + ADC combination data. The late-breaking oral presentation (LBA76) on Oct 25 is the highest-impact catalyst.
Price Chart
Executive Summary
BioNTech announced it will present 16 abstracts, including a late-breaking oral presentation of first Phase 2 data for pumitamig plus docetaxel in second-line metastatic NSCLC, at ESMO 2026 (Oct 23-27). The filing is a routine pipeline update with no financial data, and the data readouts are forward-looking with no concrete efficacy or safety numbers disclosed.
Key Facts
- 16 abstracts across 10 tumor types to be presented at ESMO 2026 (Oct 23-27, Madrid)
- Late-breaking oral presentation (LBA76) of first data from global Phase 2 ROSETTA Lung-107 trial of pumitamig + docetaxel in 2L metastatic NSCLC
- First global Phase 2 data for pumitamig + elfetabart drozuntecan (B7-H3 ADC) in advanced solid tumors (abstract #999O)
- Subgroup analysis suggests intracranial efficacy of pumitamig + chemo in SCLC/TNBC with brain metastases
- First results from Phase 2 trial of pumitamig + FOLFIRI in 2L neuroendocrine neoplasms
- BioNTech has 13 ongoing Phase 3 trials across its oncology pipeline
- No financial data, revenue, EPS, or guidance provided in this filing
Financial Impact
No financial impact disclosed; pipeline update with no revenue or earnings data
Risk Factors
- Clinical data may fail to show meaningful efficacy or safety advantage over standard of care
- Forward-looking statements subject to regulatory and development uncertainties
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001776985-26-000069 |
| Document: form6-kesmo202619oct2026.htm | 0001776985-26-000069 |
| Document: 0001776985-26-000069-index-headers.html | 0001776985-26-000069 |
| Document: 0001776985-26-000069-index.html | 0001776985-26-000069 |
| Document: 0001776985-26-000069.txt | 0001776985-26-000069 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 1d ago | 6-K | $86.86 | awaiting T+60 | awaiting T+60 | $87.06 (+0.23%) |
Oct 26, 2026 1d ago | 6-K | $86.86 | awaiting T+60 | awaiting T+60 | $87.06 (−0.23%) |
Oct 26, 2026 1d ago | Press Release | $86.86 | awaiting T+60 | awaiting T+60 | $87.06 (−0.23%) |
Oct 25, 2026 3d ago | Press Release | $86.86 | awaiting T+60 | awaiting T+60 | $87.06 (+0.23%) |
Oct 22, 2026 5d ago | 6-K | $89.67 | awaiting T+60 | awaiting T+60 | $87.06 (−2.91%) |
Oct 19, 2026 8d ago | 6-K | $89.21 | awaiting T+60 | awaiting T+60 | $87.06 (−2.41%) |
Oct 19, 2026 8d ago | Press Release | $89.21 | awaiting T+60 | awaiting T+60 | $87.06 (−2.41%) |
Oct 13, 2026 14d ago | 6-K | $88.66 | awaiting T+60 | awaiting T+60 | $87.06 (+1.80%) |
Sep 14, 2026 6w ago | 6-K | $98.86 | awaiting T+60 | awaiting T+60 | $87.06 (−11.94%) |
Sep 14, 2026 6w ago | Press Release | $98.86 | awaiting T+60 | awaiting T+60 | $87.06 (−11.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers